CR
Therapeutic Areas
Tychon Bioscience Pipeline
| Drug | Indication | Phase |
|---|---|---|
| TYC201 (Anti-EpCAM PARs) | Solid Tumors (Breast/Colon) | Pre-clinical |
| Anti-CD133 PARs | Cancer Stem Cells | Discovery |
| Anti-CD19 PARs | Leukemia/Lymphoma | Discovery |
| Universal CAR T-cell Hybrid CAR/PAR | Not Specified | Discovery |